Cipla launches authorized Aloxi generic
Cipla USA has introduced its authorized Aloxi generic (palonosetron hydrochloride 0.25 mg/5 ml) through its agreements with Helsinn Healthcare, maker of the branded product.
The drug is indicated to treat and prevent acute and delayed nausea and vomiting associated with chemotherapy. The company said that its authorized Aloxi generic was available to ship immediately.
The drug had U.S. sales of roughly $460 million for the 12 months ended November 2017.
The drug is indicated to treat and prevent acute and delayed nausea and vomiting associated with chemotherapy. The company said that its authorized Aloxi generic was available to ship immediately.
The drug had U.S. sales of roughly $460 million for the 12 months ended November 2017.